Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Otlertuzumab |
Synonyms | |
Therapy Description |
Otlertuzumab (TRU-016) is a anti-CD37 therapeutic protein, which may result in increased antibody-dependent cellular cytotoxicity and decreased tumor cell growth (PMID: 24381226, PMID: 25146490, PMID: 27977057). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Otlertuzumab | TRU-016|TRU016|TRU 016 | CD37 Antibody 8 | Otlertuzumab (TRU-016) is a anti-CD37 therapeutic protein, which may result in increased antibody-dependent cellular cytotoxicity and decreased tumor cell growth (PMID: 24381226, PMID: 25146490, PMID: 27977057). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|